Authors:
Klinkhardt, U
Graff, J
Westrup, D
Kirchmaier, CM
Esslinger, HU
Breddin, HK
Harder, S
Citation: U. Klinkhardt et al., Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects, BR J CL PH, 52(3), 2001, pp. 297-305
Authors:
Graff, J
Andries, D
Elsner, M
Westrup, D
Bassus, S
Franz, N
Klinkhardt, U
Harder, S
Citation: J. Graff et al., Platelet CD62 expression and PDCFAB secretion in patients undergoing PTCA and treatment with abciximab, BR J CL PH, 51(6), 2001, pp. 577-582
Authors:
Harder, S
Klinkhardt, U
Graff, J
Westrup, D
Kirchmaier, CM
Glusa, E
Mascelli, MA
Marciniak, SJ
Just, A
Losche, W
Breddin, HK
Citation: S. Harder et al., In vitro dose response to different GPIIb/IIIa-antagonists: Inter-laboratory comparison of various platelet function tests, THROMB RES, 102(1), 2001, pp. 39-48
Authors:
Klinkhardt, U
Kirchmaier, CM
Westrup, D
Breddin, HK
Mahnel, R
Graff, J
Hild, M
Harder, S
Citation: U. Klinkhardt et al., Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters, THROMB RES, 97(4), 2000, pp. 201-207
Authors:
Klinkhardt, U
Kirchmaier, CM
Westrup, D
Graff, J
Mahnel, R
Breddin, HK
Harder, S
Citation: U. Klinkhardt et al., Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A, CLIN PHARM, 67(3), 2000, pp. 305-313
Authors:
Harder, S
Kirchmaier, CM
Krzywanek, HJ
Westrup, D
Bae, JW
Breddin, HK
Citation: S. Harder et al., Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects, CIRCULATION, 100(11), 1999, pp. 1175-1181